LFG
MLYS icon

Larson Financial Group’s Mineralys Therapeutics MLYS Stock Holding History

Larson Financial Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$163 Sell
6
-148
-96% -$4.34K ﹤0.01% 3476
2025
Q4 		$5.59K Buy
154
+124
+413% +$4.97K ﹤0.01% 2409
2025
Q3 		$1.14K Buy
30
+24
+400% +$519 ﹤0.01% 2882
2025
Q2 		$81 Buy
+6
New +$87 ﹤0.01% 3190

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Larson Financial Group's MLYS Position: Q1 2026 in Review

Larson Financial Group reduced its Mineralys Therapeutics (MLYS) stake by 96% in Q1 2026, selling an estimated $4.34K and leaving 6 shares worth $163. The position accounts for ﹤0.01% of the portfolio, ranked #3476.

Larson Financial Group first reported a position in MLYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.59K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Larson Financial Group held 6 shares of Mineralys Therapeutics worth $163 as of Q1 2026.
  • Larson Financial Group sold 148 Mineralys Therapeutics shares in Q1 2026, an estimated $4.34K.
  • Mineralys Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3476 holding.
  • Larson Financial Group first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Mineralys Therapeutics position peaked at $5.59K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.